Deutsche Bank maintained a Buy rating on Teva Pharma (NYSE: TEVA) and raised its price target to $82.00 (from $73.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics July 28, 2015 9:23 AM Leerink Partners Raises Price Target to $84 on Teva Pharma (TEVA) Following Call with CFO July 28, 2015 8:12 AM Teva Pharma (TEVA) PT Bumped to $75 at Piper JaffrayJuly 28, 2015 7:39 AM Teva Pharma (TEVA) to Acquire Allergan Genetics (AGN) in $40.5B Cash and Stock DealJuly 27, 2015 6:03 AM Teva Withdraws Proposal to Acquire MylanJuly 27, 2015 4:31 AM Teva to Acquire Allergan Generics for $40.5 Billion Creating a Transformative Generics and Specialty Company Well Positioned to Win in Global HealthcareJuly 27, 2015 4:30 AM